Trends in HIV-drug resistant transmission stabilized
ATLANTA — One-in-six genetic sequences obtained from newly diagnosed HIV patients in the United States contained drug-resistant mutations related to three different classes of HIV drugs, researchers reported here. The rate of HIV-drug resistant transmissions has not increased significantly from 2007.
“This report highlights two important concepts,” study researcher David Kim, MD, a CDC medical officer, said during his presentation. “One, it underscores the importance of HIV genotype testing for newly diagnosed HIV-infected patients. More broadly, it emphasizes the need for continuity of HIV drug-resistance surveillance.”
Kim and colleagues obtained HIV-1 nucleotide sequence data from 18,144 patients newly diagnosed with HIV who had not been treated with antiretroviral drugs. Data were collected from 10 states and large cities from 2007 to 2010. The researchers applied the CDC’s HIV-1 mutation list — used for surveillance — to the sequence data to identify transmitted drug resistance-associated mutations (TDRMs) related to three drug classes: non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors. They also calculated the estimated annual percentage change to assess trends in TDRMs.
Of the 18,144 sequences, 2,932 (16.2%) contained 4,788 TDRMs associated with any of the three drug classes. According to the researchers, 2,461 (13.6%) of these sequences had TDRMs for a single drug class, 386 (2.1%) for two drug classes, and 85 (0.5%) for three drug classes. TDRMs associated with NNRTIs were located in 1,464 (8.1%) sequences, NRTIs in 1,206 (6.7%) sequences, and protease inhibitors in 818 (4.5%) sequences.
Although the estimated annual percentage change for any TDRMs was not significant (3%; P=.06), the researchers found a significant percentage change for TDRMs related to a single drug class (4.3%; P=.01) and for TDRMs related to NNRTIs (5.2%; P=.03).
“Continued monitoring of HIV drug resistance can help tell us what the national, regional or perhaps global trends in HIV drug resistance might look like, particularly as new drugs and new classes of drugs come on the market,” Kim said. – by John Schoen
For more information:
Kim D. #149. Presented at: 2013 Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta.
*Photograph courtesy of Matt Alexandre.
David Kim, MD, can be reached at firstname.lastname@example.org.
Disclosure: Kim reports no relevant financial disclosures.